Plain-English translation of NCT06660992 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This is a large study testing a new medication called HSK31858 to see if it can help people with non-cystic fibrosis bronchiectasis—a lung disease that causes chronic cough, mucus production, and sometimes coughing up blood. About 669 people will take part across multiple hospitals. Half will receive the medication for one year, while the other half will receive a placebo (a dummy pill) so researchers can fairly compare how well the treatment works.
Bronchiectasis is a serious lung disease that keeps getting worse, with patients experiencing repeated flare-ups and lung damage. Doctors are looking for new treatments to help prevent these flare-ups, reduce coughing and mucus, and slow the disease's progression.
You likely qualify if…
You likely don't qualify if…
You will visit the hospital or clinic regularly over 52 weeks (one year). At the start, you'll be randomly assigned to receive either the new medication or a placebo—neither you nor your doctor will know which one you're getting. You'll take your assigned treatment daily at home and come in for check-ups where doctors will monitor your breathing, cough, mucus production, and overall health. The study will track how many times you experience a lung flare-up and how well you're feeling on the medication compared to the placebo.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China